Effect of Chlorogenic Acids on Cognitive Function in Mild Cognitive Impairment: A Randomized Controlled Crossover Trial.
Aged
Aged, 80 and over
Attention
/ drug effects
Chlorogenic Acid
/ pharmacology
Cognition
/ drug effects
Cognitive Dysfunction
/ drug therapy
Cross-Over Studies
Executive Function
/ drug effects
Female
Humans
Japan
Male
Middle Aged
Neuropsychological Tests
Nootropic Agents
/ pharmacology
Treatment Outcome
Attention
chlorogenic acid
coffee
crossover studies
mild cognitive impairment
polyphenol
trail making test
Journal
Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863
Informations de publication
Date de publication:
2019
2019
Historique:
pubmed:
7
11
2019
medline:
15
12
2020
entrez:
6
11
2019
Statut:
ppublish
Résumé
Mild cognitive impairment (MCI) is a global-scale issue, due in large part to the rapidly growing elderly population. The main polyphenol contained in coffee beans, chlorogenic acid (CGA), improves attention in healthy individuals. The utility of CGAs for treating MCI, however, has not been evaluated. To determine the effects of continuous CGA intake on cognitive function, especially attention, in patients diagnosed with MCI. The study was a randomized controlled crossover trial including 34 patients with MCI. Participants were randomly divided into two groups: Those who first ingested a placebo beverage and those who first ingested an active beverage containing CGAs (553.6 mg/bottle) twice daily for 12 weeks. After a 4-week washout period, the subjects ingested the other beverage (i.e., placebo or active beverage) in the same manner. Endpoint measures included scores on the Japanese version of the Mini-Mental State Examination (MMSE), the Japanese version of the Alzheimer's Disease Assessment Scale-cognitive component (ADAS-cog) testing overall cognitive function, and the Japanese version of the Trail Making Test (TMT-A, TMT-B) testing attention, along with the results of blood tests to evaluate safety. In the TMT-B test, participants had a significantly reduced number of errors while ingesting the CGA beverage as compared with the placebo beverage (p < 0.05), although there was no difference in test completion time. Scores in the MMSE, ADAS-cog, and TMT-A did not differ significantly between conditions. Continuous intake of CGAs appears to improve attention and executive function among cognitive functions in MCI.
Sections du résumé
BACKGROUND
Mild cognitive impairment (MCI) is a global-scale issue, due in large part to the rapidly growing elderly population. The main polyphenol contained in coffee beans, chlorogenic acid (CGA), improves attention in healthy individuals. The utility of CGAs for treating MCI, however, has not been evaluated.
OBJECTIVE
To determine the effects of continuous CGA intake on cognitive function, especially attention, in patients diagnosed with MCI.
METHODS
The study was a randomized controlled crossover trial including 34 patients with MCI. Participants were randomly divided into two groups: Those who first ingested a placebo beverage and those who first ingested an active beverage containing CGAs (553.6 mg/bottle) twice daily for 12 weeks. After a 4-week washout period, the subjects ingested the other beverage (i.e., placebo or active beverage) in the same manner. Endpoint measures included scores on the Japanese version of the Mini-Mental State Examination (MMSE), the Japanese version of the Alzheimer's Disease Assessment Scale-cognitive component (ADAS-cog) testing overall cognitive function, and the Japanese version of the Trail Making Test (TMT-A, TMT-B) testing attention, along with the results of blood tests to evaluate safety.
RESULTS
In the TMT-B test, participants had a significantly reduced number of errors while ingesting the CGA beverage as compared with the placebo beverage (p < 0.05), although there was no difference in test completion time. Scores in the MMSE, ADAS-cog, and TMT-A did not differ significantly between conditions.
CONCLUSION
Continuous intake of CGAs appears to improve attention and executive function among cognitive functions in MCI.
Identifiants
pubmed: 31683483
pii: JAD190757
doi: 10.3233/JAD-190757
pmc: PMC6971825
doi:
Substances chimiques
Nootropic Agents
0
Chlorogenic Acid
318ADP12RI
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1209-1216Références
Food Sci Nutr. 2018 Oct 19;6(8):2530-2536
pubmed: 30510754
Am J Epidemiol. 2002 Nov 1;156(9):842-50
pubmed: 12397002
Am J Clin Nutr. 2014 Feb;99(2):268-75
pubmed: 24257718
J Hypertens. 2006 Jun;24(6):1065-73
pubmed: 16685206
Intelligence. 2011 Jul;39(4):222-232
pubmed: 21789028
Psychopharmacol Bull. 1983;19(3):448-50
pubmed: 6635122
Biosci Biotechnol Biochem. 2013;77(6):1329-32
pubmed: 23748773
Lancet. 2013 Oct 26;382(9902):1405-12
pubmed: 23871492
Nutr Res. 2014 Feb;34(2):155-9
pubmed: 24461317
Crit Rev Food Sci Nutr. 2011 Apr;51(4):363-73
pubmed: 21432699
Biosci Biotechnol Biochem. 2008 Mar;72(3):885-8
pubmed: 18323641
Eur J Pharmacol. 2010 Dec 15;649(1-3):210-7
pubmed: 20854806
Nutr Neurosci. 2017 Jan;20(1):32-39
pubmed: 25130715
Mol Nutr Food Res. 2005 Mar;49(3):274-84
pubmed: 15704241
Evid Based Complement Alternat Med. 2018 Mar 7;2018:8608497
pubmed: 29707036
J Geriatr Psychiatry Neurol. 2007 Jun;20(2):67-75
pubmed: 17548775
JAMA. 2005 Jul 6;294(1):97-104
pubmed: 15998896
Biosci Biotechnol Biochem. 2013;77(8):1633-6
pubmed: 23924724
Eur J Clin Nutr. 2007 Feb;61(2):226-32
pubmed: 16929246
Int J Food Sci Nutr. 2015 May;66(3):350-4
pubmed: 25666414
Clin Exp Hypertens. 2006 Jul;28(5):439-49
pubmed: 16820341
Mol Nutr Food Res. 2014 Feb;58(2):301-9
pubmed: 24039147
Nutrients. 2018 Sep 20;10(10):null
pubmed: 30241302
Sleep Med Rev. 2017 Feb;31:70-78
pubmed: 26899133
Arch Clin Neuropsychol. 2005 Jan;20(1):33-65
pubmed: 15620813
J Psychiatr Res. 1982-1983;17(1):37-49
pubmed: 7183759
Hypertens Res. 2009 Nov;32(11):969-74
pubmed: 19713967
Arch Clin Neuropsychol. 2008 Mar;23(2):129-37
pubmed: 18178372
J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Oct 15;858(1-2):96-105
pubmed: 17766198
Neurology. 1993 Nov;43(11):2412-4
pubmed: 8232972
Ann Neurol. 2002 Sep;52(3):276-84
pubmed: 12205639